Naproxen Zetpil Cf (Naproxen)

Naproxen works by reversibly inhibiting the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which are key steps in the production of prostaglandins. By reducing prostaglandin synthesis, naproxen diminishes the inflammatory response, alleviates pain signals, and helps lower elevated body temperature.

The appropriate dose of Naproxen Zetpil Cf is determined by the prescribing healthcare professional based on the patient’s condition, severity of symptoms, and individual risk factors. The prescriber will select the specific strength and frequency that best matches the therapeutic need.

Safety of naproxen during pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Naproxen has a longer half‑life than many NSAIDs such as ibuprofen, allowing less frequent dosing. Its analgesic and anti‑inflammatory potency is comparable, but the risk profile for gastrointestinal and cardiovascular events is similar across the class, requiring individual risk assessment.

Store the suppositories at room temperature, ideally below 25 °C. Keep them in the original packaging to protect from moisture and direct sunlight. Do not refrigerate or freeze, as temperature extremes can affect the suppository’s consistency.

The product is a rectal suppository. The patient should wash hands, lie on their side with the lower leg drawn toward the abdomen, gently insert the suppository into the rectum, and remain lying down for a few minutes to ensure proper absorption.

Serious risks include gastrointestinal ulceration or bleeding, cardiovascular events such as heart attack or stroke, renal impairment leading to reduced kidney function, severe skin reactions like Stevens‑Johnson syndrome, and liver injury. Patients should be monitored for any signs of these conditions.

Individuals with known hypersensitivity to naproxen or other NSAIDs, active peptic ulcer disease, severe renal or hepatic impairment, uncontrolled heart failure, or those who have experienced a recent cardiovascular event should avoid using this product. A healthcare professional should evaluate suitability before prescribing.